ArticleDiabetes spectrum : a publication of the American Diabetes Association2021
Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy.
Article in Diabetes spectrum : a publication of the American Diabetes Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Continuous glucose monitoring in noninsulin-treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta-analysis of randomised controlled trials.Diabetes, obesity & metabolism · 2025Pooled it
- Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis.BMJ open diabetes research & care · 2022Pooled it
- Dulce Digital-Me: results of a randomized comparative trial of static versus adaptive digital interventions for Latine adults with diabetes.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2025Trial
- Real-time continuous glucose monitoring related to reductions in inpatient and emergency department encounters and their associated costs among non-insulin-treated people with type 2 diabetes.Journal of managed care & specialty pharmacy · 2026Article
- Outcomes of Diabetes Management with Continuous Glucose Monitoring Technology.Archives of internal medicine research · 2026Article
- A multicenter prospective evaluation of the benefits of Dexcom ONE + in subjects with type 2 diabetes on insulin therapy beyond glycemic control: results from the LIFE-ONE study.Acta diabetologica · 2026Article
- Economic burden of type 2 diabetes management in France according to clinical characteristics.Diabetes, obesity & metabolism · 2026Article
- The Expanding Role of Continuous Glucose Monitoring in the Management and Prevention of Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Article
- Use of Continuous Glucose Monitors in Publicly Insured Youth With Type 2 Diabetes: A 12-month Pilot and Feasibility Study.Journal of diabetes science and technology · 2025Article
- Exploring Combined Use of Continuous Glucose Monitoring and Anti-Diabetes Medications on Glycaemic Control for People With Type 2 Diabetes Not Using Insulin.Endocrinology, diabetes & metabolism · 2025 · on this mapObservational
- Quantitative estimation of disposition index from postprandial glucose data across the spectrum of glucose tolerance.American journal of physiology. Endocrinology and metabolism · 2025Article
- Enhancing Type 2 Diabetes Care With CGM Integration: Insights From an Italian Expert Group.Diabetes/metabolism research and reviews · 2025Review
- Assessing glycaemic impact of FreeStyle libre monitoring in patients with insulin-treated type 2 diabetes: a retrospective real-world analysis.Journal of diabetes and metabolic disorders · 2025Article
- The role of advanced technologies in improving diabetes outcomes.The American journal of managed care · 2025Review
- Removing barriers to management of adults with type 2 diabetes on insulin using continuous glucose monitoring in UK primary care practice: An expert consensus.Diabetic medicine : a journal of the British Diabetic Association · 2025Article
- Addition of continuous glucose monitoring to glucagon-like peptide 1 receptor agonist treatment for type 2 diabetes mellitus - An economic evaluation.Journal of managed care & specialty pharmacy · 2025Article
- Intermittently scanned continuous glucose monitoring compared with blood glucose monitoring is associated with lower HbADiabetologia · 2025Article
- Persistent Performance Improvement Using Team Resources and Continuous Glucose Monitoring in Patients With Poorly Controlled Type 2 Diabetes.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Initiating continuous glucose monitoring is associated with improvements in glycemic control and reduced health care resource utilization for people with diabetes in a large US-insured population: A real-world evidence study.Journal of managed care & specialty pharmacy · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlycemic control is suboptimal in many individuals with type 2 diabetes. Although use of flash continuous glucose monitoring (CGM) has demonstrated A1C reductions in patients with type 2 diabetes treated with a multiple daily injection or insulin pump therapy regimen, the glycemic benefit of this technology in patients with type 2 diabetes using nonintensive treatment regimens has not been well studied.
methodsThis retrospective, observational study used the IBM Explorys database to assess changes in A1C after flash CGM prescription in a large population with suboptimally controlled type 2 diabetes treated with nonintensive therapy. Inclusion criteria were diagnosis of type 2 diabetes, age <65 years, treatment with basal insulin or noninsulin therapy, naive to any CGM, baseline A1C ≥8%, and a prescription for the FreeStyle Libre flash CGM system during the period between October 2017 and February 2020. Patients served as their own control subject.
resultsA total of 1,034 adults with type 2 diabetes (mean age 51.6 ± 9.2 years, 50.9% male, baseline A1C 10.1 ± 1.7%) were assessed. More patients received noninsulin treatments (
conclusionPrescription of the flash CGM system was associated with significant reductions in A1C in patients with type 2 diabetes treated with basal insulin or noninsulin therapy. These findings provide evidence for expanding access to flash CGM within the broader population of people with type 2 diabetes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.